With 0.82 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.03 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $53.855 whereas the lowest price it dropped to was $50.861. The 52-week range on CELC shows that it touched its highest point at $53.40 and its lowest point at $7.57 during that stretch. It currently has a 1-year price target of $67.14. Beta for the stock currently stands at 0.73.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CELC was up-trending over the past week, with a rise of 12.88%, but this was up by 276.65% over a month. Three-month performance surged to 392.30% while six-month performance rose 310.38%. The stock gained 295.65% in the past year, while it has gained 207.91% so far this year. A look at the trailing 12-month EPS for CELC yields -3.45 with Next year EPS estimates of -4.00. For the next quarter, that number is -1.01. This implies an EPS growth rate of -38.87% for this year and -1.89% for next year. EPS is expected to grow by 26.69% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -31.53%.
Float and Shares Shorts:
At present, 38.91 million CELC shares are outstanding with a float of 33.50 million shares on hand for trading. On 2025-07-31, short shares totaled 3.09 million, which was 752.0 higher than short shares on 1751241600. In addition to Mr. Brian F. Sullivan as the firm’s Co-Founder, Chairman & CEO, Dr. Lance G. Laing Ph.D. serves as its Co-Founder, Chief Science Officer, VP, Secretary & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, CELC reported revenue of $0.0 and operating income of -$36133000.0. The EBITDA in the recently reported quarter was -$33777000.0 and diluted EPS was -$0.86.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CELC since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CELC analysts setting a high price target of 79.0 and a low target of 50.0, the average target price over the next 12 months is 67.14286. Based on these targets, CELC could surge 52.54% to reach the target high and fall by -3.46% to reach the target low. Reaching the average price target will result in a growth of 29.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.29765 being high and -$2.78928 being low. For CELC, this leads to a yearly average estimate of -$2.62875. The surprise factor in the prior quarter was -$0.86. Based on analyst estimates, the high estimate for the next quarter is -$1.02 and the low estimate is -$1.05. The average estimate for the next quarter is thus -$1.03.
